Owusu Enid, Amartey Benjamin T, Afutu Emmanuel, Boafo Neal
Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, University of Ghana, Accra 233, Ghana.
Department of Audiology, Speech and Language Therapy, School of Biomedical and Allied Health Sciences, University of Ghana, Accra 233, Ghana.
Diseases. 2022 Feb 1;10(1):10. doi: 10.3390/diseases10010010.
Background: Hearing impairment (HI) is a major problem in Ghana; however, the few attempts at shedding light on its causes appear to overlook the adverse effects of some medications—a gap that this study sought to fill. Aminoglycoside therapy for tuberculosis (TB) treatment is one of these medications. Aim: The aim of this study was to establish the potential of aminoglycoside as a cause of hearing impairment among patients on anti-TB treatment. Method: This was a case−control study, involving patients receiving treatment for TB with aminoglycoside at the chest clinic of the Tema General Hospital and a control group of age- and gender-matched healthy volunteers. A structured questionnaire was administered to obtain the demographic data and case history of the participants. The hearing sensitivity of the participants was assessed using conventional pure tone audiometry and transient evoked otoacoustic emission tests. Results: A hearing loss prevalence of 20% (12/60) was found among patients receiving treatment for TB, with the intensity of impairment ranging from mild to severe. Hearing thresholds of patients receiving anti-TB medications were significantly elevated (p < 0.05) in comparison to the thresholds of the control group, especially at the high frequencies. Conclusion: This study shows that aminoglycoside therapy for tuberculosis may contribute to hearing impairment among tuberculosis patients in Ghana. Audiological management of these patients should therefore be an essential part of their therapeutic treatment plan.
听力障碍（HI）在加纳是一个主要问题；然而，以往少数试图阐明其病因的研究似乎忽略了某些药物的不良影响——本研究旨在填补这一空白。用于治疗结核病（TB）的氨基糖苷类药物就是其中之一。目的：本研究的目的是确定氨基糖苷类药物在接受抗结核治疗的患者中导致听力障碍的可能性。方法：这是一项病例对照研究，涉及在特马总医院胸科诊所接受氨基糖苷类药物治疗结核病的患者以及年龄和性别匹配的健康志愿者对照组。通过发放结构化问卷来获取参与者的人口统计学数据和病史。使用传统纯音听力测定法和瞬态诱发耳声发射测试评估参与者的听力敏感度。结果：在接受结核病治疗的患者中发现听力损失患病率为20%（12/60），损伤程度从轻度到重度不等。与对照组相比，接受抗结核药物治疗的患者的听力阈值显著升高（p < 0.05），尤其是在高频段。结论：本研究表明，在加纳，用于治疗结核病的氨基糖苷类药物可能导致结核病患者出现听力障碍。因此，对这些患者进行听力学管理应成为其治疗计划的重要组成部分。
